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Abstract The third-generation aromatase inhibitors (AIs)
letrozole, anastrozole, and exemestane are replacing
tamoxifen as adjuvant therapy in most postmenopausal
women with early breast cancer. Although AIs have dem-
onstrated superior efﬁcacy and better overall safety
compared with tamoxifen in randomized controlled trials,
they may not provide the cardioprotective effects of
tamoxifen, and bone loss may be a concern with their long-
term adjuvant use. Patients require regular bone mineral
density monitoring, and prophylactic bisphosphonates are
being evaluated to determine whether they may protect
long-term bone health. AIs decrease the risks of thrombo-
embolic and cerebrovascular events compared with
tamoxifen, and the overall rate of cardiovascular events in
patients treated with AIs is within the range seen in age-
matched, non-breast-cancer populations. AIs are also
associated with a lower incidence of endometrial cancer
and fewer vaginal bleeding/discharge events than tamoxi-
fen. Compared with tamoxifen, the incidence of hot ﬂashes
is lower with anastrozole and letrozole but may be higher
with exemestane. Generally, adverse events with AIs are
predictable and manageable, whereas tamoxifen may be
associated with life-threatening events in a minority of
patients. Overall, the beneﬁts of AIs over tamoxifen are
achieved without compromising overall quality of life.
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Introduction
Tamoxifen became the standard adjuvant therapy for
women with early breast cancer following the ﬁrst dem-
onstration of efﬁcacy more than 20 years ago [1].
Administration of tamoxifen for 5 years has been shown to
reduce breast cancer recurrence by 41% and mortality by
34% in women with hormone-responsive tumors [2].
Nevertheless, many limitations of tamoxifen have emerged
with widespread use. In the landmark National Surgical
Adjuvant Breast and Bowel Project B-14 trial, 66% of
tamoxifen-treated patients experienced side effects com-
pared with 58% of patients given placebo [3]. Severe,
potentially life-threatening events such as thrombosis were
more likely to occur in patients aged[60 years [3]. Long-
term adverse effects associated with 5 years’ adjuvant
tamoxifen include venous thromboembolic events, vaginal
bleeding, vaginal discharge, ischemic cerebrovascular
events, endometrial and uterine cancer, and hysterectomy
[3, 4]. Experiencing side effects signiﬁcantly increases the
likelihood of patients discontinuing tamoxifen therapy
(odds ratio 4.0; 95% conﬁdence interval [CI] 1.1, 13.9 in
women aged ‡ 55 years) [5]. Over time, resistance to
tamoxifen may develop [6], and therapy beyond 5 years is
not recommended because neither further disease-free
survival nor survival beneﬁt is gained [7].
The third-generation aromatase inhibitors (AIs) letroz-
ole, anastrozole, and exemestane are rapidly replacing
tamoxifen as initial adjuvant therapy [8, 9] or sequential
adjuvant therapy after 2–5 years of tamoxifen [10–13]. By
potently inhibiting the aromatase enzyme, which converts
androgens to estrogen [14, 15], AIs achieve almost total
suppression of total body aromatization and dramatic
reductions in estrogen concentrations in postmenopausal
women [16–18]. AIs are now recommended in
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cancer [19–21]. In addition, guidance is being developed
for the management of common co-morbidities such as
osteoporosis in postmenopausal women with hormone-
sensitive breast cancer receiving AIs [20, 22]. This review
examines the safety of AIs and assesses their advantages
and disadvantages compared with tamoxifen. It also con-
siders the impact of treatment on co-morbidities commonly
encountered in this population.
Possible impact of treatment on common co-morbidities
Adjuvant therapy should be individualized on the basis of
clinical and biologic risk factors [21], including the pres-
ence of co-morbidities [23–26]. The most prevalent co-
morbidities in the postmenopausal patient population are
hypertension, arthritis, heart disease, diabetes, chronic
obstructive pulmonary disease, eye problems, anemia,
depression, fractures, hearing problems, osteoporosis,
Parkinson’s disease, renal failure, and urinary tract prob-
lems [25]. Understanding the long-term effects of
aromatase inhibition on bone and cardiovascular health are
particularly important to consider because of the potential
effects of altering estrogen concentrations.
Bone disease
Bone health typically may deteriorate as women age, par-
ticularly after reaching menopause [27, 28]. A decline in
estrogen concentrations accelerates postmenopausal bone
loss [29–31] while vitamin D deﬁciency also increases
bone turnover and the risk of fracture [32, 33]. It is
important to note that bone health is compromised in
women with breast cancer compared with the general
population [34]. In the Women’s Health Initiative Obser-
vational Study, breast cancer survivors had signiﬁcantly
lower total body bone mineral density (BMD) and total hip
BMD [34] and a signiﬁcantly higher risk of clinical frac-
tures [35]. Of concern, osteoporosis was undiagnosed in
more than three quarters of breast cancer survivors and the
reference population [34]. Multiple factors contribute to the
increased risk of osteoporosis and fractures in postmeno-
pausal women with breast cancer [34]. Furthermore, tumor
cells can have a direct effect on bone remodeling [36], and
breast cancer therapy can lead to cancer treatment-induced
bone loss (CTIBL) [37–39]. In a large cohort study,
patients with early breast cancer who received anticancer
therapy had a 30% higher risk for osteoporosis/osteopenia
(odds ratio 1.29; 95% CI 1.13, 1.46) [38]. The study also
showed that other factors such as poor health status, history
of smoking, and alcohol abuse can contribute to CTIBL.
The most serious consequence of CTIBL is an increased
risk of fractures (Fig. 1)[ 35], which increase morbidity and
healthcare costs [40]. The presence of bone metastases can
contribute to CTIBL and lead to serious complications,
including fractures, spinal compression, bone pain, and
hypercalcemia of malignancy [41].
Aromatase inhibitors and bone disease
In a recent study, the bone health of 1,354 patients with
breast cancer receiving an AI (anastrozole, exemestane, or
letrozole) was compared with 11,014 controls [39]. Treat-
ment with an AI increased the risk of bone loss (relative
risk 1.3; 95% CI 1.1, 1.6; P = 0.01) and bone fracture
(relative risk 1.4; 95% CI 1.2, 1.6; P = 0.001). The risks
remained signiﬁcantly higher for AI therapy after adjust-
ment for age and co-morbidities [39]. An increase in the
incidence of arthralgia is noted with all three AIs, when
compared with tamoxifen.
Anastrozole
Howell and colleagues reported fracture rates after a
median follow-up of 68 months in the Arimidex, Tamox-
ifen, Alone or in Combination (ATAC) trial [42]. Fractures
were reported in 577 (9.3%) of the 6,186 patients and were
more common with anastrozole than with tamoxifen (11 vs.
8%, respectively; P\0.0001). The incidence of hip frac-
tures was 1% in both groups. The rate of fractures was low
at approximately 2% per year and decreased to baseline
levels after completion of 5 years of treatment. The effects
of anastrozole and tamoxifen on BMD were assessed in a
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Fig. 1 Age-standardized fracture incident rates by survivor status.
Standardized rates were calculated using the age distribution of the
entire Women’s Health Initiative Observational Study cohort. Excess
numbers of fractures per 10,000 person-years are above each set of
bars [35].  2005 American Medical Association. Reproduced with
permission
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123sub-analysis of 167 patients from the ATAC trial [43]. An-
astrozole-treated patients had signiﬁcant decreases in lumbar
spine BMD (–8.1%; 95% CI –10.1, –6.1; P\0.0001) and
total hip BMD (–7.4%; 95% CI –9.6, –5.3; P\0.0001) rel-
ative to tamoxifen-treated patients, in whom small increases
were observed. Bone loss was greatest in the ﬁrst 2 years of
anastrozoletreatment,asreportedpreviously[44],buttherate
oflossappearedtoslowdownfromyears2to5.Intheupdated
analysisafteramedianfollow-upof68 months,osteopeniaor
osteoporosis was reported in 11% of patients receiving anas-
trozole compared with7% receivingtamoxifen (P\0.0001)
[42, 45]. Another sub-analysis of the ATAC trial showed that
the majority of joint symptoms occur within 24 months of
initiatingtreatment[46].After68 months’medianfollow-up,
jointsymptomswerereportedin35.6and29.4%ofpatientsin
the anastrozole and tamoxifen arms, respectively. Most
symptomsweremildinintensity,and46%werereportedasan
exacerbation of a pre-existing condition. The incidence of
serious joint symptoms was similar for anastrozole and
tamoxifen (10.6 vs. 10.4%, respectively) and only 2.1 and
0.9%, respectively, discontinued treatment because of joint
symptoms. After a median follow-up of 68 months, muscle
crampswerelesscommonwithanastrozolethantamoxifen(4
vs. 8%, respectively; P\0.0001), whereas carpal-tunnel
syndrome was more common with anastrozole (3 vs. 1%,
respectively; P\0.0001) [42].
TheseupdatedresultsfromtheATACtrialconﬁrmthatAIs
are a well-tolerated initial treatment option in terms of bone
health [43, 45, 46]. Although anastrozole is associated with
BMD loss, no patient with normal bone at baseline became
osteoporotic after 5 years of treatment, and the rate of bone
loss in the lumbar spine region slowed down in years 2–5.
The ARNO/ABCSG8 trials investigated the efﬁcacy and
safety of switching to anastrozole after 2 years of tamox-
ifen [12]. Although there were signiﬁcantly more fractures
in patients switching to anastrozole (2.1%) than in those
continuing on tamoxifen (1.0%) [12], the rate was lower
than that seen at a similar point in the ATAC trial [12]. In
the Italian Tamoxifen Anastrozole (ITA) trial, switching to
anastrozole after 2–3 years of tamoxifen was not associ-
ated with an increase in fracture rate, although differences
may emerge with longer follow-up [13].
Letrozole
In the Breast International Group (BIG) 1–98 trial of initial
adjuvant therapy, there was a slight yet signiﬁcant differ-
ence in the incidence of fractures (5.7% with letrozole vs.
4.0% with tamoxifen; P\0.001) [8]. The MA.17 trial of
extended adjuvant therapy showed that when compared
with placebo, letrozole had no signiﬁcant impact on frac-
tures [10]. There was a small but signiﬁcant difference in
patient-reported diagnoses of new-onset osteoporosis (8%
letrozole vs. 6% placebo, P = 0.003), and arthralgia and
myalgia were signiﬁcantly more common with letrozole
than placebo [10]. A companion study to MA.17 demon-
strated a signiﬁcant decrease in lumbar spine BMD (–5.35
vs. –0.70%; P = 0.008) and total hip BMD (–3.6 vs.
–0.71%; P = 0.044) over 2 years in patients treated with
letrozole compared with placebo, although no patient went
below the threshold for osteoporosis in total hip BMD [47].
Data from this companion study suggest that women with a
BMD score of –1.0 or greater when starting letrozole after
tamoxifen are less vulnerable to enhanced bone resorption
and may not require prophylactic bisphosphonate therapy.
Exemestane
In a model of ovariectomized rats, the steroidal AI exe-
mestane was shown to prevent bone loss, presumably via
its androgenic properties (both exemestane and its metab-
olite 17-hydro-exemestane demonstrate afﬁnity for the
androgen receptor) [48]. However, a randomized study to
compare the effects of progestins and AIs on bone
remodeling markers in patients with metastatic breast
cancer found that exemestane increased osteoclast activity
[49]. In the adjuvant treatment setting, a randomized trial
involving 147 patients with early breast cancer demon-
strated a non-signiﬁcant effect of exemestane compared
with placebo on the annual rate of BMD loss in the lumbar
spine (2.17 vs. 1.84%; P = 0.568) and a small but signiﬁ-
cant effect in the femoral neck (2.72 vs. 1.48%; P = 0.024)
[50]. Of note was the ﬁnding that BMD may rapidly
improve following AI discontinuation: this trial showed
that bone resorption markers returned to or below baseline
values, and bone formation markers remained moderately
increased within 6 months of stopping exemestane [51].
In the Intergroup Exemestane Study (IES) of exemes-
tane following 2–3 years of tamoxifen, fractures were
reported more frequently with exemestane than with
tamoxifen after a median follow-up of 30.6 months,
although this difference was not statistically signiﬁcant (3.1
vs. 2.3%; P = 0.08) [52]. However, the difference in inci-
dence of fractures was statistically signiﬁcant (7.0% with
exemestane vs. 4.9% with tamoxifen; P = 0.003) after a
median follow-up of 55.7 months [11]. The incidence of
osteoporosis was also signiﬁcantly higher with exemestane
than with tamoxifen (9.2 vs. 7.2%, respectively; P = 0.01).
Recent results from a 1-year sub-study revealed that
patients on exemestane experienced a signiﬁcant decrease
in hip BMD, while patients on tamoxifen did not [53].
These results were conﬁrmed by another recent study,
which evaluated the effects of exemestane on bone turn-
over markers and BMD in 70 postmenopausal women
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123(62.0 ± 8.9 years) with early breast cancer who were
switched to exemestane after 2–3 years on tamoxifen [54].
Patients in the exemestane group had a signiﬁcant decrease
in BMD and early parathyroid hormone (at month 6) and
an increase in bone alkaline phosphatase (B-ALP) and
the carboxy-terminal telopeptide of type I collagen
after 24 months. These studies suggest that switching
postmenopausal women from tamoxifen to exemestane
causes a marked increase in bone turnover markers with a
consequent reduction in BMD.
Arthralgia was also signiﬁcantly more common with
exemestane than with tamoxifen (5.4 vs. 3.6%, P = 0.01)
in the IES [52]. A study by Lønning et al. discovered a
high prevalence of vitamin D deﬁciency in postmenopausal
women treated with exemestane (52 of 59 patients) or
placebo (56 of 62 patients), and this could be the most
important factor causing bone loss in both groups [55].
Vitamin D substitution is therefore recommended for
postmenopausal women, particularly those with breast
cancer receiving an AI. The incidence of carpal-tunnel
syndrome in the IES was higher in the exemestane arm
(2.8%) than in the tamoxifen arm (0.4%; P\0.001) [11].
Comparative studies of aromatase inhibitors
A randomized trial (Letrozole, Exemestane, and Anas-
trozole Pharmacodynamics [LEAP]) of healthy volunteers
demonstrated that letrozole, exemestane, and anastrozole
have similar effects on bone biochemical measurements
and all result in increases in bone turnover [56]. There were
no statistically signiﬁcant differences between the AIs in
changes from baseline to 24 weeks for B-ALP, serum C-
telopeptide crosslinks, and propeptide of type I procolla-
gen. The only difference in the bone remodeling markers
was a greater decrease in parathyroid hormone with exe-
mestane than with anastrozole (P = 0.04).
Thus, all AIs seem to have similar effects on bone
health. The ATAC bone sub-study results are reassuring for
the entire AI class, and women with breast cancer who
have normal BMD measurements at the onset of AI treat-
ment may be able to undergo 5 years of therapy without the
risk of developing osteoporosis. Patients at risk of clini-
cally relevant BMD loss during treatment should be
identiﬁed and managed according to evolving clinical
guidelines [20, 57].
Bisphosphonates
In the American Society of Clinical Oncology (ASCO)
guidelines postmenopausal patients with breast cancer
w h or e c e i v eA I sa r ei d e n t i ﬁ e da sb e i n ga th i g hr i s kf o r
osteoporosis, and it is recommended that they have
baseline BMD evaluation and regular monitoring to
guide subsequent therapeutic interventions such as bis-
phosphonates [20, 58]. Preliminary results have been
reported from a small number of clinical trials of bis-
phosphonates in women receiving adjuvant AI therapy.
In one trial, premenopausal breast cancer patients
receiving goserelin plus anastrozole or goserelin plus
tamoxifen were randomly assigned to the bisphosphonate
zoledronic acid (ZA) (4 mg IV every 6 months) or pla-
cebo. After 36 months, it was shown that ZA given
every 6 months helped prevent bone loss in these pre-
menopausal patients in both the lumbar spine and hip
regardless of endocrine therapy [59]. Two randomized
trials have shown that bisphosphonates may be beneﬁcial
in postmenopausal patients at a higher risk of osteopo-
rosis [60, 61]. In the Zometa-Femara Adjuvant Synergy
Trial (Z-FAST) (North American) trial, 602 postmeno-
pausal women with hormone-responsive breast cancer
starting adjuvant therapy with letrozole were randomized
to receive upfront ZA (4 mg IV infusion every
6 months) or delayed ZA when indicated (either post-
baseline T-score decreases\–2 SD or occurrence of
fracture) [60, 62]. Preliminary results after 12 months’
follow-up indicate that initial treatment with ZA may be
used to prevent CTIBL, and results at 24 months conﬁrm
these initial ﬁndings [62, 63] although the rate of clinical
fractures was not changed. In addition, the small pro-
portion of patients (8%) requiring ZA in the ﬁrst year
highlights the short-term bone tolerability of letrozole
[62]. Results from the similarly designed ZO-FAST
(European; N = 1,065) trial also support the use of ZA
to potentially manage CTIBL in postmenopausal women
with early breast cancer receiving adjuvant letrozole
[61].
Lipid metabolism: A cohort study demonstrated that
total and low-density lipoprotein (LDL) cholesterol con-
centrations are positively correlated with years since
diagnosis of breast cancer [64]. In addition, during meno-
pause, women experience adverse changes in
cardiovascular risk factors, including declines in concen-
trations of high-density lipoprotein (HDL) cholesterol and
increases in concentrations of total cholesterol, LDL cho-
lesterol, HDL3 cholesterol, and triglycerides [65, 66].
These changes are independent of age and body mass
index.
Assessing the impact of AIs on lipid proﬁles is difﬁcult
in trials where tamoxifen is the comparator. The selective
estrogen-receptor modulators (SERMs) such as tamoxifen
are known to have lipid-lowering properties [67, 68]. What
is clear is that the studies comparing AIs with tamoxifen
indicate only that the AIs lack the lipid-lowering effects of
tamoxifen.
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Anastrozole
In the ATAC trial, the incidence of hypercholesterolemia
was higher in patients receiving anastrozole than tamoxifen
(9 vs. 3%, respectively; P\0.0001) [42]. In the ITA trial,
lipid metabolism disorders were reported in 9.3% of
patients treated with anastrozole and 4.0% receiving
tamoxifen (P = 0.04) [13].
A recent multicenter study in patients with estrogen-
receptor positive breast cancer investigated the effects of
adjuvant anastrozole and toremifene, a SERM, on serum
lipids [68]. Results showed that only toremifene had a ben-
eﬁcial effect on lipid proﬁle, indicated by a decrease in total
cholesterol, LDL cholesterol, triglycerides, and apolipopro-
tein B, and an increase in HDL cholesterol and
apolipoprotein A1. Changes in total cholesterol, HDL, LDL,
and apolipoproteins were signiﬁcantly different between
toremifene and anastrozole at 6 and 12 months (P\0.05).
Letrozole
In the BIG 1–98 trial, according to the protocol, cholesterol
concentrations (fasting or non-fasting) were collected sys-
tematically in the case-report forms every 6 months and
even patients with only a single measurement above the
upper limit of normal were deﬁned as hypercholesterol-
emic [8]. Hypercholesterolemia was reported in 5.4% of
the letrozole arm compared with 1.2% of the tamoxifen
arm in patients with baseline values within normal limits,
who then had an increase of 1.5 times the upper limit of
normal [69]. Hypercholesterolemia was typically a single
event and in the majority of these patients (80%) occurred
at only grade 1 intensity (meaning a slight numerical
increase above normal, not requiring medications). More-
over, the majority of cases were single measurements
collected in non-fasting patients. Furthermore, when
looking at total serum cholesterol levels, there was a 12%
median decrease from baseline in total cholesterol in the
tamoxifen arm after 6 months, consistent with previous
reports demonstrating the lipid-lowering effect of tamoxi-
fen [67], while in the letrozole group total cholesterol
values remained stable [8]. Hypercholesterolemia was not
predeﬁned as an adverse event in the ATAC trial, and lipid
concentrations were not routinely assessed [42].
Exemestane
Hypercholesterolemia was not reported in the IES trial of
sequential exemestane after tamoxifen [11, 52].
Another study examined the longitudinal changes in
body composition and lipid proﬁles in 55 postmenopausal
women with early breast cancer switched to exemestane
after at least 2 years of tamoxifen treatment [70]. Fat
mass signiﬁcantly decreased (P\0.01) while the fat-free
mass to fat mass ratio signiﬁcantly increased (P\0.05)
by month 12 in the exemestane but not in the tamoxifen
group. In addition, triglycerides and HDL cholesterol
signiﬁcantly decreased (P\0.01 and P\0.05, respec-
tively) in the exemestane group, while LDL cholesterol
signiﬁcantly increased (P\0.01) at the end of the 1-year
study period.
Aromatase inhibitors versus placebo
When compared with placebo (the most accurate way to
assess the true impact of AIs on serum lipids), the ﬁnal
analysis of the MA.17 trial demonstrated the incidence of
hypercholesterolemia was 16% in the letrozole and the
placebo arms [10]. Results from an MA.17 lipid sub-study
showed that in 347 postmenopausal women with primary
breast cancer treated for up to 36 months, letrozole
(n = 183) does not signiﬁcantly alter lipid proﬁle (samples
drawn under fasting conditions) compared with placebo
(n = 164) [71]. In a placebo-controlled study involving 147
postmenopausal women with early breast cancer, exemes-
tane had no major effect on lipid proﬁle except for a
modest but signiﬁcant decrease from baseline in HDL
cholesterol (P\0.001) and apolipoprotein A1 (P = 0.004)
[50]. On the basis of these results, it is clear that when
compared with placebo, AIs do not have a detrimental
effect on lipid proﬁle. However, it should be noted that
there have been no placebo-controlled trials of adjuvant
anastrozole in women with breast cancer.
Comparative studies of aromatase inhibitors
The LEAP trial directly compared safety parameters
between the steroidal AI exemestane and the non-steroidal
AIs anastrozole and letrozole in 90 healthy postmenopausal
women (Table 1)[ 72]. Initial results from the trial showed
that there were no signiﬁcant differences between anas-
trozole and letrozole in effects on LDL:HDL ratios,
triglyceride concentrations, and non-HDL concentrations.
Exemestane was associated with an increase in LDL:HDL
ratio (+17) (P = 0.047) compared with anastrozole. There
was no median change from baseline in total serum cho-
lesterol for letrozole, a slight increase for anastrozole
(+0.4), and a non-signiﬁcant decrease for exemestane
(–3.9) (P = 0.164 vs. anastrozole) [72].
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Cardiovascular risk increases substantially and progressively
in women aged ‡65 years [73–77]. Isolated systolic hyper-
tension, associated with arterial stiffening, is predominant in
middle- and older-aged hypertensives [75] and predisposes
individuals to coronary heart disease, heart failure, stroke,
vascular dementia, and chronic kidney disease [73]. The risk
of cardiac disease is also inﬂuenced by ethnicity, smoking,
obesity, physical inactivity, alcohol abuse, and the presence
of co-morbid diseases such as diabetes.
In patients with breast cancer the presence of co-mor-
bidities, including cardiovascular disease and diabetes, is
associated with a poorer prognosis than when co-morbid
disease is absent [78] and may explain disparities in outcome
between different ethnic groups [79]. There is also evidence
that breast cancer is associated with a higher prevalence of
hypertension compared with other tumor types [80]a n da
signiﬁcantly increased risk of stroke compared with the
general population (relative risk 1.12; 95% CI 1.07, 1.17)
[81]. Many breast cancer therapies increase the risk of car-
diovascular events [82–88]; tamoxifen, however, may have
some cardio-protective effects [89, 90].
Tamoxifen and cardiovascular disease
Several studies have demonstrated the potential cardiopro-
tective properties of tamoxifen, including a reduction in
hospital admissions due to cardiac disease [89–91]a n d
decreased mortality from cardiac disease [92]. In a
meta-analysis, tamoxifen was associated with a signiﬁcantly
decreased incidence of myocardial infarction (relative risk
0.90) and death from myocardial infarction (relative risk
0.62) [93]. This ﬁnding is consistent with results from an
earlier cohort study [94] and the Early Breast Cancer Trial-
ists’ Collaborative Group (EBCTCG) meta-analysis, which
demonstrated decreases in the risk of cardiac death and
overall mortality from vascular disease in patients receiving
tamoxifen compared with those receiving placebo [2].
Aromatase inhibitors and cardiovascular disease
Assessing the impact of different AIs on cardiovascular
disease in postmenopausal women with breast cancer is
difﬁcult and inter-trial comparisons are confounded by
differences in data collection and end points; for example,
in the BIG 1–98 trial all potential adverse events were
predeﬁned in the case-report forms whereas the ATAC trial
used non-speciﬁc case-report forms to report adverse
events [8, 95]. Furthermore, comparisons with tamoxifen
are complicated by its cardioprotective properties. Placebo-
controlled trials thus provide the best source of data to
delineate the effects of AIs in a patient population with an
inherently elevated risk of cardiac events.
Anastrozole
The ATAC trial provided data on the cardiovascular effects
of anastrozole as initial adjuvant therapy compared with
Table 1 Comparative effects of third-generation aromatase inhibitors on lipids [72]
Percentage change
from baseline
Anastrozole
(n = 29)
Letrozole
(n = 29)
P value vs.
anastrozole
Exemestane
(n = 32)
P value vs.
anastrozole
Total cholesterol
Week 12 –2.3 –3.8 0.617 –5.5 0.262
Week 24 +0.4 –0.0 0.900 –3.9 0.164
Triglycerides
Week 12 –2.9 +9.6 0.037 –7.7 0.417
Week 24 +0.3 +5.4 0.550 +2.1 0.827
Ratio of LDL-C:HDL-C
Week 12 –0.0 –3.1 0.486 +8.8 0.048
Week 24 +4.6 +3.4 0.847 +17.0 0.047
Non-HDL-C
Week 12 –2.7 –4.2 0.667 –3.5 0.820
Week 24 +1.3 +1.2 0.975 –0.6 0.630
Ratio of apo B:apo A1
Week 12 –1.0 –3.3 0.452 +4.4 0.069
Week 24 +0.0 –0.8 0.842 +9.0 0.023
LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein, apo B apolipoprotein B, apo A1 apolipoprotein A1
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123tamoxifen. The incidence of ischemic cardiovascular dis-
ease was higher (but not signiﬁcantly) with anastrozole
than placebo (127/3092, 4.1% vs. 104/3094, 3.4%;
P = 0.1). The incidence of angina was also higher with
anastrozole (71/3092, 2.3% vs. 51/3094, 1.6%; P = 0.07),
while myocardial infarction occurred with similar fre-
quency (37/3092, 1.2% vs. 34/3094, 1.1%; P = 0.7 [42].
Hypertension was statistically signiﬁcantly more common
with anastrozole than with tamoxifen (13 vs. 11%,
respectively; P = 0.04) [42]. In the ARNO95 trial vascular
events, including hot ﬂashes, ischemic cardiovascular
events, deep vein thrombosis, and ischemic cerebrovascu-
lar events, occurred in 9.2% of the anastrozole arm
compared with 8.8% of the tamoxifen arm [96].
Letrozole
The BIG 1–98 trial demonstrated a similar incidence of
cardiac events in the letrozole and tamoxifen groups (4.1
vs. 3.8%, respectively; not signiﬁcant). However, more
women in the letrozole group had grade 3, 4, or 5 cardiac
events (2.1 vs. 1.1%, respectively; P\0.001), but these
events remain rare [8]. Of note, a recent update of the
monotherapy arms of BIG 1–98 after a longer median
follow-up of 51 months showed that the overall incidence
of cardiac events was comparable in the two groups (134
events [5.5%] in the letrozole group vs. 122 [5.0%] in the
tamoxifen arm), thus conﬁrming the safe cardiac proﬁle of
letrozole reported at 26 months [97].
Exemestane
In the IES, there was no signiﬁcant difference between
exemestane and tamoxifen in the incidence of combined
cardiovascular disease/thromboembolic events (22.1 vs.
20.9%, respectively; P = 0.34) after a median follow-up of
55.7 months [11]. The incidence of myocardial infarction
was higher with exemestane than with tamoxifen, although
the difference between treatment groups was not signiﬁcant
(1.3 vs. 0.8%, respectively; P = 0.08) [11].
Overall, the rate of cardiovascular events in patients
treated with AIs is well within the range seen in age-mat-
ched, non-breast-cancer populations; for example, for
women 57–65 years of age, the rates of fatal myocardial
infarction and other fatal coronary artery disease are 1.1
and 0.81 per 1,000 patient-years, respectively [98]. Similar
rates were recorded in the UK General Practice Research
Database and Swedish MI register [99]. Currently, there is
insufﬁcient information to fully determine the effect of AIs
on cardiovascular disease, especially coronary heart
disease.
Aromatase inhibitors versus placebo
Cardiovascular events occurred with similar frequency in
the letrozole and placebo arms in the MA.17 trial (5.8 vs.
5.6%, respectively; P = 0.76) [10]. Similar incidences
were reported in the letrozole and placebo arms for stroke/
transient ischemic attack (0.7 vs. 0.6%, respectively),
myocardial infarction (0.3 vs. 0.4%, respectively), new or
worsening angina (1.2 vs. 0.9%), angina requiring coronary
artery bypass graft (0.2 vs. 0.5%), and thromboembolic
events (0.4 vs. 0.2%, respectively) [10]. These results
clearly indicate that when compared with placebo, AIs do
not have a detrimental effect on cardiovascular safety.
Gynecologic health
The onset of menopause is characterized by numerous
adverse events associated with a decline in estrogen con-
centrations [100–102]. Early symptoms include abnormal
vaginal bleeding, hot ﬂashes, and mood changes, while
vaginal dryness and irritation, osteoporosis, and heart dis-
ease are late symptoms [29, 103, 104]. Vasomotor
symptoms, particularly hot ﬂashes, are common during
transition to menopause [105–109] and may lead to dis-
turbed sleep, depressive symptoms, and signiﬁcant
reductions in quality of life [110–115]. Cigarette smoking
may be associated with increased risk of hot ﬂashes in
menopausal women [116]. Sexual dysfunction is also pre-
valent in menopausal women and is associated with vaginal
atrophy, vaginal/genital dryness, dyspareunia (pain during
sexual intercourse), vaginitis, cystitis, and urinary tract
infections [117].
Aromatase inhibitors and gynecologic health
Anastrozole
In the ATAC trial, the incidence of hot ﬂashes was sig-
niﬁcantly lower with anastrozole than with tamoxifen (36
vs. 41%; P\0.0001) [9]. In the latest analysis, anastrozole
was associated with a signiﬁcantly lower incidence of
gynecologic events (endometrial hyperplasia, endometrial
neoplasia, cervical neoplasm, and enlarged uterine ﬁbroids:
3 vs. 10% with tamoxifen; P\0.0001) [42]. A quality-of-
life (QOL) analysis conﬁrmed that vaginal discharge,
vaginal itching/irritation, and vaginal bleeding were less
common with anastrozole but found that vaginal dryness,
pain during intercourse, and loss of interest in sex were
more common [118]. After 2 years of treatment there was a
non-signiﬁcant trend towards a lower incidence of endo-
metrial abnormalities with anastrozole than tamoxifen
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The latest update of the ATAC trial revealed reduced libido
in signiﬁcantly more patients receiving anastrozole (1%)
than tamoxifen (\1%; P = 0.0001) [42]. Patients receiving
anastrozole also experienced a signiﬁcantly higher inci-
dence of dyspareunia than those receiving tamoxifen
(1 vs.\1%, respectively; P = 0.002), whereas urinary
incontinence and urinary tract infection were signiﬁcantly
less common among patients receiving anastrozole (uri-
nary incontinence: 2 vs. 4%, respectively, P\0.0001;
urinary tract infection: 8 vs. 10%, respectively, P = 0.002).
In a randomized study of postmenopausal women in
whom abnormal vaginal bleeding and/or asymptomatic
endometrial thickening occurred during treatment with
tamoxifen, switching to anastrozole was associated with a
signiﬁcant reduction in mean endometrial thickness com-
pared with continuation of tamoxifen (P\0.0001) [120].
Signiﬁcantly fewer anastrozole patients required a repeat
hysteroscopy and dilation and curettage compared with
those taking tamoxifen (4.8 vs. 33.0%, respectively;
P\0.0001).
Letrozole
In the BIG 1–98 trial [8], endometrial biopsies were sig-
niﬁcantly less common in patients receiving letrozole than
tamoxifen (2.3 vs. 9.1%, respectively; P\0.001), and
there was a trend towards fewer invasive endometrial
cancers (0.1 vs. 0.3%, respectively; not signiﬁcant). There
was a signiﬁcantly lower incidence of vaginal bleeding
with letrozole than with tamoxifen (3.3 vs. 6.6%, respec-
tively; P\0.001), and the incidence of hot ﬂashes was
also signiﬁcantly lower (33.5 vs. 38.0%, respectively;
P\0.001). In another study in patients intolerant of
tamoxifen, switching to letrozole for 6 weeks was associ-
ated with a 53.7% decrease in hot ﬂashes (hot-ﬂash score
97.0–52.1; P = 0.001) [121]. In the MA.17 trial, letrozole
was associated with less vaginal bleeding than placebo (6
vs. 8%, respectively; P = 0.005) but a greater incidence of
hot ﬂashes (58 vs. 54%, respectively; P = 0.003) [10].
There was no signiﬁcant difference in the incidence of
vaginal dryness between letrozole and placebo.
Exemestane
In the IES, there were no signiﬁcant differences between
the exemestane and tamoxifen treatment arms in the inci-
dence of endometrial cancer (0.4 vs. 0.7%, respectively;
P = 0.17) [11], or the incidence of hot ﬂashes (42 vs. 40%,
respectively; P = 0.28) [52]. Overall, gynecologic symp-
toms were lower with exemestane than with tamoxifen
(6 vs. 9%; P\0.001) [52]; however, vaginal dryness was
signiﬁcantly more common among women taking exe-
mestane than those taking tamoxifen, while vaginal
discharge was signiﬁcantly more common with tamoxifen
[122]. Vaginal bleeding was signiﬁcantly more common in
the tamoxifen arm (7.1%) than in the exemestane group
(4.8%; P = 0.001) [11].
Other adverse events
Secondary cancer
The association between tamoxifen and endometrial and
uterine cancers is well-established [4] and is not observed
with AIs. However, a safety analysis of the ATAC trial
[42] showed a surprisingly higher incidence of head and
neck cancer with anastrozole compared with tamoxifen
(10/3092 vs. 3/3094, respectively). Similarly, there was an
excess of lung cancer (25/3092 vs. 16/3094) and lung
cancer deaths with anastrozole; however, further analyses
are required to conﬁrm these ﬁndings. Of note, a higher
incidence of secondary cancer was not noted in the IES (72
events exemestane vs. 107 tamoxifen) or in the BIG 1–98
trial (69 letrozole vs. 82 tamoxifen) [8, 11].
A meta-analysis showed that tamoxifen is associated
with a modest but statistically signiﬁcant increase in the
risk of developing gastrointestinal cancer (relative risk
1.31; 95% CI 1.01, 1.69), particularly for postmenopausal
women (relative risk 1.77) [93].
Gastrointestinal health
Diarrhea was signiﬁcantly more common among patients
receiving the steroidal AI exemestane than in those taking
tamoxifen (4.2 vs. 2.2%, respectively) [123] but is not a
typical side effect of the non-steroidal AIs letrozole and
anastrozole. However, an updated safety analysis of the
ATAC trial showed that anastrozole was associated with an
increased incidence of diarrhea compared with tamoxifen
(9 vs. 7%; P = 0.02) [42].
Neurologic effects and visual disturbance
It has been suggested that endocrine therapy may affect
cognitive function in patients with breast cancer [124]. In a
study comparing patients from the ATAC trial with healthy
controls, anastrozole was associated with signiﬁcant
impairments in a processing speed task and on a measure of
immediate verbal memory [125]. Another study conducted
in healthy, estrogen-treated postmenopausal women treated
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inhibition on cognition [126].
The impact of adjuvant AI therapy on cognition and
other neurologic processes is clearly an important issue that
will require further studies in the future. Neurologic effects
reported with exemestane, including dizziness and vertigo
[127] and signiﬁcantly more visual disturbances compared
with tamoxifen [52], are not characteristic of non-steroidal
AIs.
Dry mouth
The latest analysis of the ATAC trial demonstrated a sig-
niﬁcantly greater incidence of dry mouth in patients
receiving anastrozole (4%) compared with tamoxifen (2%;
P = 0.003) [42].
Cosmetic effects
Weight gain is common after breast cancer therapy and
increases the risk of recurrence, cardiovascular disease, and
diabetes [64]. A study of Japanese patients showed that
more women reported weight gain in the anastrozole group
than in the tamoxifen group (35.8 vs. 12.5%, respectively;
P £ 0.0036) [128], but no difference was seen among
patients from the ATAC trial included in a QOL sub-
analysis [118].
The androgen structure of exemestane may lead to
androgenic side effects. Hypertrichosis, hair loss, hoarse-
ness, and acne were reported in about 10% of patients
treated with daily exemestane doses of 200 mg or more in
dose-ﬁnding studies [129, 130], but have not emerged as a
signiﬁcant issue in phase II or phase III trials with this
agent.
Anastrozole treatment was associated with a lower
incidence of nail disorders (2 vs. 3%; P = 0.002) and
fungal infection (1 vs. 1%; p = 0.01) compared with
tamoxifen [42].
Quality of life and patient preference
Anastrozole
The QOL of patients treated in the ATAC trial was studied
during a 5-year follow-up period [118, 131]. Anastrozole
and tamoxifen had similar overall effects on QOL (Func-
tional Assessment of Cancer Therapy-Breast [FACT-B]
trial outcome index plus endocrine sub-scale) in the ﬁrst
2 years of treatment [118], and an initial worsening of
endocrine symptoms gradually improved over time [131].
The authors concluded that the beneﬁts of anastrozole are
achieved without detrimental effects on QOL. However,
another study conducted in Japanese patients demonstrated
that FACT-G, FACT-B, and FACT-ES scores were sig-
niﬁcantly better with tamoxifen than with anastrozole
(P = 0.012, P = 0.010, and P = 0.015, respectively) [132].
Letrozole
The MA.17 and BIG 1–98 trials have demonstrated that
adjuvant letrozole is well-tolerated compared with placebo
[10] and better tolerated than tamoxifen [8]. In another
study of postmenopausal women who were experiencing
distressing side effects while taking adjuvant tamoxifen
and were switched to letrozole, after 6 weeks 66% of
patients preferred to remain on letrozole, 24% preferred to
go back to tamoxifen, and 10% stopped all therapy [121].
In the placebo-controlled MA.17 trial, letrozole signiﬁ-
cantly improved outcomes and did not impair overall QOL
[133] (Fig. 2). Minor differences seen in some domains
(physical functioning, bodily pain, vitality, vasomotor, and
sexual) were consistent with a minority of patients expe-
riencing changes in QOL compatible with a reduction in
estrogen synthesis. A sub-analysis of US subjects in MA.17
demonstrated no signiﬁcant differences between letrozole
and placebo in overall QOL summary scores (mental and
physical) and ﬁve of eight sub-domains of SF-36 [134].
There were no differences in SF-36 mental and physical
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Fig. 2 Mean change score in Short Form 36-item Health Survey. A
positive score indicates a favorable change in quality of life. (A)
Physical component summary; P = not signiﬁcant for all time points.
(B) Mental component summary; P = not signiﬁcant for all time
points. [133].  2005 American Society of Clinical Oncology.
Reproduced with permission
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psychosocial and physical domains [134].
Exemestane
Results from the IES QOL sub-protocol indicate that
switching to exemestane from tamoxifen improves out-
come without a signiﬁcant detrimental impact upon QOL
[135]. At entry, there was a high prevalence of severe
endocrine symptoms (vasomotor complaints and sexual
problems), and these persisted with exemestane and
tamoxifen during the study. No signiﬁcant differences
between groups were seen for any endocrine symptoms
apart from vaginal discharge, which was more pronounced
with tamoxifen (P\0.001).
Conclusions
Clinical trials show that the third-generation AIs lack the
serious risks of thromboembolism and endometrial cancers
associated with tamoxifen and are generally well tolerated,
with the majority of adverse events occurring at mild to
moderate intensity [8–11].
AIs are associated with a mild to modest increased risk
of osteoporosis compared with tamoxifen, and it is there-
fore essential that patients have regular BMD assessments
and be monitored proactively to minimize the risk of
clinical fractures [20, 57]. The increased risk of fractures
with an AI compared with tamoxifen needs to be balanced
against the increased risk of endometrial and cerebrovas-
cular/thromboembolic morbidity with tamoxifen [136]. Of
note, the updated ATAC analysis shows that the majority
of excess adverse events associated with tamoxifen
occurred during the ﬁrst 2.5 years of treatment; there were
142 (8%) fewer predeﬁned adverse events in the anas-
trozole arm [137]. Thus, it appears that many excess
gynecologic, thromboembolic, and cerebrovascular adverse
effects occurring in tamoxifen-treated patients could be
avoided if patients were treated initially with an AI [136].
Although AIs do not have the cholesterol-lowering and
potential cardioprotective properties of tamoxifen, they do
not signiﬁcantly worsen total cholesterol concentrations
and do not appear to increase cardiovascular risk when
compared with placebo. Nevertheless, it is prudent to rec-
ommend that all patients at risk of cardiovascular effects
are properly monitored and managed, and all breast cancer
patients should be routinely monitored for cardiovascular
disease. It is difﬁcult to draw meaningful conclusions from
comparisons of randomized trials of tamoxifen versus an-
astrozole, letrozole, or exemestane because of differences
in assessing and reporting risk of cardiovascular disease [8,
52, 95, 138].
Current information is insufﬁcient to determine the
effects of AIs on cardiovascular disease and coronary heart
disease risk [20]. Similarly, further follow-up is required to
determine the late consequences of AI therapy [20].
Despite these provisos, ASCO now recommends that
optimal adjuvant hormonal therapy for a postmenopausal
woman with receptor-positive breast cancer includes an AI
as initial therapy or after treatment with tamoxifen. Results
from several ongoing trials, including the Femara versus
Anastrozole Clinical Evaluation, MA.27, the National
Surgical Adjuvant Breast and Bowel Project, LATER, and
MILER, should provide more information on the long-term
tolerance and the optimal duration of adjuvant AI therapy
and help determine which strategy has the best ratio of
efﬁcacy to tolerance.
In conclusion, the efﬁcacy beneﬁts of AIs outweigh the
risks when AIs are used as adjuvant therapy in postmen-
opausal women with early breast cancer. Safety, QOL, and
patient preference must all be considered in the determi-
nation of the optimal strategy for long-term endocrine
therapy, bearing in mind that patients may require treat-
ment for 10 years or more. Every patient is unique, and
endocrine therapy must be individualized according to
clinical, biologic, and patient factors such as lifestyle, the
presence of signiﬁcant co-morbidities, and use of con-
comitant medications. Tolerability should no longer be an
obstacle to effective, long-term endocrine therapy.
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